ALFA Finder| Management target | Revenue 25.0% FY27 |
|---|
| Revenue growth | H1 revenue ₹667 Cr, down ~2% YoY; timing-driven per management. |
|---|---|
| Margins | H1 EBITDA margin 23%; FY27 guided 24-25%; OptraSCAN drags. |
| Order book | Central procurement orders in hand; no order book figure disclosed. |
| Demand visibility | Rate contract renewed; orders in hand; hepatitis demand building. |
| Management confidence | Confident; repeatedly reiterates 25% guidance despite soft H1. |
Growth
Revenue fell about 2% YoY to ₹667 Cr, which management attributes to timing rather than demand. H1 PAT of ₹60 Cr was softer on OptraSCAN interest and amortisation.
Outlook
Guides 25% FY27 top-line growth and a 24-25% EBITDA margin. H2 is expected to contribute about 60% of annual revenue.
Risks
Government tender timing and rate-contract delays can swing quarters. OptraSCAN carries a ₹15 Cr H1 EBITDA loss, and FY27 targets depend on a heavy H2 catch-up.
Last quarter's promises, checked
Delivered
- OptraScan not profitable FY27 → H1 EBITDA loss ₹15 Cr (= BEAT)
- ₹72 Cr automation from ₹200 Cr IPO → ₹72 Cr automation capex ordered (= BEAT)
Partly delivered
- 24–25% FY27 EBITDA margin → H1 margin 23% (= PARTIAL)
- 2,200–2,600 devices FY27 → H1 559 devices (= PARTIAL, H2-dependent)
Missed
- 25% FY27 top-line growth → H1 revenue ₹667 Cr, down ~2% YoY (= MISS to date)
Earnings Call Transcript filed with BSE, NSE: MOLBIO. Summary written with AI assistance from the document.
Molbio Diagnostics Ltd: key numbers
- Share price
- ₹1,318.60
- Market cap
- ₹15,196 Cr
- Revenue (annual)
- ₹1,446 Cr
- Net profit (annual)
- ₹166.6 Cr
- P/E (TTM)
- 98.4×Sector 54.5×
- Promoter holding
- 41.29%
- FII holding
- 1.59%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Molbio Diagnostics Ltd
All →Molbio Diagnostics Other Announcement
Molbio Diagnostics filed CRISIL's monitoring agency report on IPO proceeds utilisation for the quarter ended 30 September 2026. The report states no deviation from the issue objects.
Molbio Diagnostics Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹259 Cr (-55% YoY), PAT ₹7.7 Cr (-93%). H1 FY27 revenue ₹667 Cr (-2%), PAT ₹60 Cr (-27%). Management reiterates 25% FY27 topline growth target.
- Call
- Guides 25% growth
Molbio Diagnostics Q2 FY27 Results: Net Profit ₹7.7 Cr, Down 92.8% YoY
Molbio Diagnostics Ltd reported revenue from operations of ₹259 Cr (-55.4% YoY) and net profit of ₹7.7 Cr (-92.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹7.7 Cr · -92.8% YoY
Molbio Diagnostics Board Meeting Date
Molbio Diagnostics' Board is scheduled for November 5, 2026, to approve Q1 and H1 results. Trading window stays closed until 48 hours post-declaration.
Molbio Diagnostics Price Movement Clarification
Molbio Diagnostics responded to NSE's spurt-in-volume query, stating the movement is purely market-driven. No pending price-sensitive information is slated for disclosure.
Molbio Diagnostics Other Announcement
Molbio Diagnostics Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026. This disclosure provides information on promoter and public shareholding structures.